Rethinking SLE Treatment: Recent Approvals, Novel Targets, and What’s Next
Living RheumRethinking SLE Treatment: Recent Approvals, Novel Targets, and What’s Next
Understanding Preload Deficiency in SLE: A New Look at Fatigue and Exercise Intolerance
Living RheumUnderstanding Preload Deficiency in SLE: A New Look at Fatigue and Exercise Intolerance
Exploring Cadherin-6: A Key Driver of Inflammation in Rheumatoid Arthritis
Living RheumExploring Cadherin-6: A Key Driver of Inflammation in Rheumatoid Arthritis
Cadherin-6 in Focus: Existing Antibodies, Emerging Applications
Living RheumCadherin-6 in Focus: Existing Antibodies, Emerging Applications
TYK2 Inhibition with Zasocitinib Delivers Early Benefit Across PsA Domains
DermConsultTYK2 Inhibition with Zasocitinib Delivers Early Benefit Across PsA Domains
Adverse Childhood Experiences in cSLE: A Clinically Significant but Underrecognized Burden
Living RheumAdverse Childhood Experiences in cSLE: A Clinically Significant but Underrecognized Burden
- advertisement
- 5 questions
- 5 questions
- advertisement
Understanding Dual Inhibition of IL-17
Medical Industry FeatureUnderstanding Dual Inhibition of IL-17
What Is Macrophage Activation Syndrome?
Medical Industry FeatureWhat Is Macrophage Activation Syndrome?
Fibrodysplasia Ossificans Progressiva: Mechanism of Disease
Medical Industry FeatureFibrodysplasia Ossificans Progressiva: Mechanism of Disease
From Primary Care to Rheumatology: Evolving PMR Management in an Era of Innovative Treatment Options
Medical Industry FeatureFrom Primary Care to Rheumatology: Evolving PMR Management in an Era of Innovative Treatment Options
- 12/12/2025
- 12/11/2025
- 12/11/2025
- 12/11/2025
- 12/09/2025
- 12/08/2025